Feed Category: Mental Health Index

NEW YORK (AP) — NEW YORK (AP) — Anavex Life Sciences Corp. (AVXL) on Monday reported a loss of $11.6 million in its fiscal fourth…

Politics·Associated PressAfter investigating Jan. 6, House GOP sides with Trump and goes after Liz CheneyWrapping up their own investigation on the Jan. 6 2021 Capitol…

Politics·The HillSenate Democrats livid with exiting Sinema, Manchin: ‘Pathetic’Senate Democrats were livid after Sens. Kyrsten Sinema (I-Ariz.) and Joe Manchin (I-W.Va.), two longtime members of…

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made…

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because…

SAN711 treats essential tremor, a neurological disorder characterised by involuntary shaking. Credit: CGN089/Shutterstock. Acadia Pharmaceuticals has secured an exclusive global licence from Saniona to develop…

The trial considered dalzanemdor to treat cognitive impairment in Huntington’s disease patients. Credit: Kateryna Kon / Shutterstock. Sage Therapeutics announced yesterday (20 November) that its…

Sage Therapeutics is shelving one of its most important experimental drugs, after a last-ditch effort to prove it can be useful in nerve-destroying disorders ended…

Net Operating Loss Reduction: 74% reduction in net operating losses compared to Q3 2023. Net Loss: Reduced to $1.6 million in Q3 2024 from $6.1…

Net Operating Loss Reduction: 74% reduction in net operating losses compared to Q3 2023. Net Loss: Reduced to $1.6 million in Q3 2024 from $6.1…

Net Revenue for IGALMI: $214,000 for Q3 2024, compared to $341,000 for Q3 2023. Net Revenue for Nine Months Ended September 30, 2024: $1.9 million,…

Net Revenue for IGALMI: $214,000 for Q3 2024, compared to $341,000 for Q3 2023. Net Revenue for Nine Months Ended September 30, 2024: $1.9 million,…